A 40-year-old female patient, non-smoker, with no comorbidities or family history of cancer and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1 presented to our hospital with complaints of pain in the left side of the chest and fever that persisted for 3 months....given the presence of both, an EGFR exon-19 deletion and ALK-1 amplification, the patient was advised tyrosine kinase inhibitors (TKIs) targeting both the alterations...she was restarted on ceritinib at a dose of 300 mg once daily (with food) and gefitinib at a dose of 250 mg once daily. Currently, at 30 months from the diagnosis of adenocarcinoma of the lung, the patient is alive and continues to receive TKIs directed at both EGFR and ALK alterations, with control of symptoms and radiologically stable disease.